Redmile Group LLC 13D and 13G filings for Stoke Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 9:00 pm Purchase |
2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK |
Redmile Group LLC | 4,713,509 9.000% |
2,088,003 (+79.53%) |
Filing |
| 2024-02-14 4:26 pm Sale |
2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK |
Redmile Group LLC | 2,625,506 5.900% |
-1,541,469 (-36.99%) |
Filing |
| 2023-02-03 5:16 pm Purchase |
2022-12-31 | 13G | Stoke Therapeutics, Inc. STOK |
Redmile Group LLC | 4,166,975 9.700% |
1,920,307 (+85.47%) |
Filing |
| 2022-02-14 5:07 pm Sale |
2021-12-31 | 13G | Stoke Therapeutics, Inc. STOK |
Redmile Group LLC | 2,246,668 6.100% |
-439,566 (-16.36%) |
Filing |
| 2021-02-16 4:09 pm Purchase |
2020-12-31 | 13G | Stoke Therapeutics, Inc. STOK |
Redmile Group LLC | 2,686,234 7.400% |
2,686,234 (New Position) |
Filing |